

Use of Murine Models of Cytokine-Secreting Tumor Vaccines Toxicity Issues Critical to Designing Clinical Trials

Journal of Immunotherapy

18, 1-9

DOI: 10.1097/00002371-199507000-00001

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cytokine Gene Transduction in the Immunotherapy of Cancer. <i>Advances in Pharmacology</i> , 1997, 40, 259-307.	1.2	43
2	Considerations for the Clinical Development of Cytokine Gene-Transduced Tumor Cell Vaccines. <i>Methods</i> , 1997, 12, 143-153.	1.9	37
3	Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer. <i>Gene Therapy</i> , 1998, 5, 869-879.	2.3	14
4	Development of Human Granulocyte-Macrophage Colony-Stimulating Factor-Transfected Tumor Cell Vaccines for the Treatment of Spontaneous Canine Cancer. <i>Human Gene Therapy</i> , 1998, 9, 1851-1861.	1.4	56
5	Enhanced Tumor Protection by Granulocyte-Macrophage Colony-Stimulating Factor Expression at the Site of an Allogeneic Vaccine. <i>Human Gene Therapy</i> , 1998, 9, 835-843.	1.4	89
6	A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma. The Johns Hopkins Oncology Center, Baltimore, Maryland. <i>Human Gene Therapy</i> , 1998, 9, 1951-1971.	1.4	78
7	Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. <i>Cancer Gene Therapy</i> , 1999, 6, 26-36.	2.2	50
8	A Universal Granulocyte-Macrophage Colony-Stimulating Factor-Producing Bystander Cell Line for Use in the Formulation of Autologous Tumor Cell-Based Vaccines. <i>Human Gene Therapy</i> , 1999, 10, 1983-1991.	1.4	105
9	New Developments in the Therapy of Acute Myelocytic Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 69-89.	0.9	17
10	Intracranial Paracrine Interleukin-2 Therapy Stimulates Prolonged Antitumor Immunity That Extends Outside the Central Nervous System. <i>Journal of Immunotherapy</i> , 2000, 23, 438-448.	1.2	26
11	Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. <i>Journal of Immunotherapy</i> , 2000, 23, 725-730.		64
12	Influence of organ site and tumor cell type on MUC1-specific tumor immunity. <i>International Immunology</i> , 2001, 13, 233-240.	1.8	20
13	Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. <i>Cellular Immunology</i> , 2003, 225, 65-74.	1.4	49
14	Genetically Engineered Tumor Cell Vaccine in a Head and Neck Cancer Model. <i>Laryngoscope</i> , 2003, 113, 552-556.	1.1	21
15	Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells. <i>Clinical Immunology</i> , 2003, 108, 8-20.	1.4	22
16	Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. <i>Blood</i> , 2003, 101, 1718-1726.	0.6	124
17	A Phase I Vaccine Safety and Chemotherapy Dose-Finding Trial of an Allogeneic GM-CSF Secreting Breast Cancer Vaccine Given in a Specifically Timed Sequence with Immunomodulatory Doses of Cyclophosphamide and Doxorubicin. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. <i>Human Gene Therapy</i> , 2004, 15, 313-337.	1.4	39
18	High-Dose Granulocyte-Macrophage Colony-Stimulating Factor-Producing Vaccines Impair the Immune Response through the Recruitment of Myeloid Suppressor Cells. <i>Cancer Research</i> , 2004, 64, 6337-6343.	0.4	477

#	ARTICLE	IF	CITATIONS
19	Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility. <i>Cytotherapy</i> , 2005, 7, 46-56.	0.3	11
20	Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen. <i>Clinical Immunology</i> , 2005, 114, 307-319.	1.4	4
21	Granulocyte-macrophage colony-stimulating factor α -transduced allogeneic cancer cellular immunotherapy: The GVAX α vaccine for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 419-424.	0.8	141
22	Granulocyte Macrophage Colony-Stimulating Factor α -Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 3883-3891.	3.2	221
23	Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. <i>Gene Therapy</i> , 2007, 14, 1639-1649.	2.3	84
24	Research Advances in Neuroblastoma Immunotherapy. <i>Current Pediatric Reviews</i> , 2009, 5, 112-117.	0.4	3
25	Melanoma Immunotherapy. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 620-642.	1.9	13
26	Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 290-295.	0.8	2
27	Sipuleucel-T for the treatment of metastatic prostate cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 509-519.	1.4	16
30	New Developments in the Therapy of Acute Myelocytic Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 69-89.	0.9	2
31	New Developments in the Therapy of Acute Myelocytic Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 69-89.	0.9	2
32	Vaccination Against the Mouse B16 Melanoma: Irradiated Tumor Cells Mixed with Liposome-Encapsulated IL-2 as an Alternative to IL-2 Gene Transfected Tumor Cells. , 1997, , 1242-1249.		0
33	Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by Ex Vivo Granulocyte-Macrophage Colony-Stimulating Factor Gene Transfer. <i>Journal of Urology</i> , 1998, , 617-618.	0.2	89
34	Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. <i>Cancer Research</i> , 1997, 57, 1537-46.	0.4	316